Published in Gynecol Oncol on November 28, 2006
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell (2008) 2.21
Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs (2010) 1.51
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol (2008) 1.31
Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imaging (2007) 1.23
Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules. Proc Natl Acad Sci U S A (2013) 1.23
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol (2009) 1.14
Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res (2008) 1.13
Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol (2009) 1.12
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol (2008) 1.07
A current review of targeted therapeutics for ovarian cancer. J Oncol (2010) 1.02
Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol (2011) 0.97
Targeting the EGF receptor for ovarian cancer therapy. J Oncol (2009) 0.96
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics. J Ovarian Res (2010) 0.93
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Targeted therapies in epithelial ovarian cancer. J Oncol (2010) 0.89
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol (2012) 0.87
A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer. Nanomedicine (2013) 0.85
Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol (2010) 0.85
Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability. Carcinogenesis (2014) 0.85
Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer. Int J Mol Sci (2011) 0.84
Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol (2012) 0.83
Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery. Mol Cell Proteomics (2012) 0.81
Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med (2009) 0.81
Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells. J Hematol Oncol (2014) 0.81
Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am (2012) 0.79
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers. Toxins (Basel) (2016) 0.78
Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells. J Exp Clin Cancer Res (2014) 0.78
Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg (2012) 0.78
Efficient blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab. Mol Cancer (2011) 0.78
Targeted therapies in epithelial ovarian cancer. Cancers (Basel) (2010) 0.77
High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation. Cancer Cell Int (2015) 0.77
Polyclonal rabbit anti-human ovarian cancer globulins inhibit tumor growth through apoptosis involving the caspase signaling. Sci Rep (2014) 0.77
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol (2010) 0.76
Clinical utility of targeted treatments in the management of epithelial ovarian cancer. Biologics (2012) 0.75
Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget (2017) 0.75
Targeted therapy in ovarian cancer. Womens Health (Lond Engl) (2016) 0.75
Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs (2016) 0.75
Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med (2000) 11.54
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med (1989) 2.81
Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective, randomized study. Crit Care Med (1994) 2.73
Liberation from mechanical ventilation: a decade of progress. Chest (1998) 2.72
The physiological function of nitrate reduction in Clostridium perfringens. J Gen Microbiol (1975) 2.60
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
Rifampicin inhibition of ribonucleic acid and protein synthesis in normal and ethylenediaminetetraacetic acid-treated Escherichia coli. J Bacteriol (1970) 2.19
Effects of a medical intensivist on patient care in a community teaching hospital. Mayo Clin Proc (1997) 2.17
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol (1997) 2.17
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol (2004) 2.08
Metered-dose inhaler versus nebulized albuterol in mechanically ventilated patients. Am Rev Respir Dis (1993) 2.05
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem (1994) 1.91
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol (2001) 1.89
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol (1995) 1.80
The use of adjuvant radiation therapy by members of the Society of Gynecologic Oncologists. Gynecol Oncol (1999) 1.79
Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer. J Natl Cancer Inst (1995) 1.79
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res (2001) 1.76
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann Oncol (2009) 1.67
Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody. Aust N Z J Med (1984) 1.55
Inhaled helium-oxygen revisited: effect of inhaled helium-oxygen during the treatment of status asthmaticus in children. J Pediatr (1997) 1.55
The impact of morbid obesity on oxygen cost of breathing (VO(2RESP)) at rest. Am J Respir Crit Care Med (1999) 1.53
Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol (2001) 1.52
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood (2000) 1.47
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol (1998) 1.46
Acute or chronic respiratory failure. Assessment and management of patients with COPD in the emergency setting. JAMA (1989) 1.45
The controversy over emergency research. A review of the issues and suggestions for a resolution. Am J Respir Crit Care Med (1996) 1.44
Endodontics--patient performed. ASDC J Dent Child (1969) 1.44
Use of the pulmonary artery catheter in critically ill patients: was invention the mother of necessity? JAMA (2000) 1.44
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol (1996) 1.43
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res (1998) 1.42
Multiple facial eccrine hidrocystomas: effective topical therapy with atropine. Br J Dermatol (1998) 1.42
Administration of therapeutic aerosols to mechanically ventilated patients. Chest (1994) 1.41
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer. Ann Pharmacother (1996) 1.38
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res (2000) 1.33
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol (1999) 1.32
The role of nonrandomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther (2015) 1.32
Real-time ultrasound-guided femoral vein catheterization during cardiopulmonary resuscitation. Ann Emerg Med (1997) 1.31
Effect of cooling on oxygen consumption in febrile critically ill patients. Am J Respir Crit Care Med (1995) 1.26
Time off work and financial implications of genitourinary medicine clinic attendance. Int J STD AIDS (1995) 1.24
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol (1994) 1.23
Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol (1993) 1.20
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer (2010) 1.19
Two-stage plans for patient accrual in phase II cancer clinical trials. Cancer Treat Rep (1980) 1.19
Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol (2001) 1.16
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood (1997) 1.15
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer (1994) 1.15
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol (2007) 1.14
Outcomes of critically ill cancer patients in a university hospital setting. Am J Respir Crit Care Med (1999) 1.12
A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother (1998) 1.10
Carcinoma of unknown primary site. Cancer (2000) 1.09
Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. J Biol Chem (1999) 1.08
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol (1999) 1.06
Heliox improves pulsus paradoxus and peak expiratory flow in nonintubated patients with severe asthma. Am J Respir Crit Care Med (1995) 1.06
Outcomes of critically ill patients denied consideration for liver transplantation. Am J Respir Crit Care Med (2000) 1.05
Increased hydrogen peroxide in the expired breath of patients with acute hypoxemic respiratory failure. Chest (1989) 1.04
Mutant loricrin is not crosslinked into the cornified cell envelope but is translocated into the nucleus in loricrin keratoderma. J Invest Dermatol (2000) 1.03
Spectrum of dominant mutations in the desmosomal cadherin desmoglein 1, causing the skin disease striate palmoplantar keratoderma. Eur J Hum Genet (2001) 1.03
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer (2013) 1.03
Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood (1992) 1.03
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol (1999) 1.02
Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst (1994) 1.02
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs (1992) 1.01
Endotoxin in human disease. Part 1: Biochemistry, assay, and possible role in diverse disease states. Chest (1993) 1.01
Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer (1995) 1.01
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol (2000) 1.00
The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest (2000) 1.00
Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol (1995) 1.00
BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer (2006) 0.99
The assessment and management of adults with status asthmaticus. Am J Respir Crit Care Med (1995) 0.99
Malignant mesothelioma of the tunica vaginalis testis. J Clin Oncol (1984) 0.99
Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med (1999) 0.98
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol (1995) 0.98
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol (1996) 0.98
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR Am J Roentgenol (1979) 0.97
Yellow nails, lymphedema and pleural effusion. Treatment of chronic pleural effusion with pleuroperitoneal shunting. Chest (1990) 0.97
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol (1998) 0.97
Sexual dysfunction following vulvectomy. Gynecol Oncol (2000) 0.96
Sedation of critically ill patients during mechanical ventilation. A comparison of propofol and midazolam. Am J Respir Crit Care Med (1996) 0.96
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol (1997) 0.96
Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. Gynecol Oncol (1994) 0.96
The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients. Chest (1999) 0.96
Dissimilatory nitrate reduction in Clostridium tertium. Z Allg Mikrobiol (1977) 0.95
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Cancer Res (1997) 0.95
Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol (1995) 0.95
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs (2006) 0.94
The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer--a potential tool for breast cancer risk assessment and biomarker evaluation. Cancer Epidemiol Biomarkers Prev (2007) 0.94
Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs (1994) 0.92
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer (2000) 0.92
The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med (2000) 0.92
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res (2010) 0.92
Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J (2001) 0.92
Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. Ann Oncol (1994) 0.91
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol (1994) 0.91